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ABSTRACT 
Objective: The present study was aimed to develop once-daily controlled release tri-layer matrix tablets of tolcapone, to achieve zero-order drug 
release for sustained plasma concentration by Geomatrix.  
Methods: Tolcapone trilayer matrix tablets were prepared by direct compression method and consisted of active middle layer with different grades 
of hydroxypropyl methylcellulose (HPMC), ethyl cellulose and sodium CMC. Barrier layers were prepared with Eudragit L100-55, guar gum, sodium 
CMC and DCP.  
Results: Based on the evaluation parameters, drug dissolution profile and release order kinetics, formulation HF16 was found to be optimized 
formulation. The developed drug delivery system provided prolonged drug release rates over a period of 24 h. The release profile of the optimized 
formulation (HF16) was described by the zero-order and best fitted to Higuchi model. FT-IR and DSC studies confirmed that there was no chemical 
interaction between drug and excipients used in the formulation. The Tmax of the optimized formulation HF16 was significantly different (p<0.05) from 
that of the marketed product. Low Tmax value for the marketed product (2.02±0.02 h) indicates rapid absorption while the higher Tmax of the optimized 
formulation (6.00±0.04 h) suggests slower absorption. This delayed absorption of test preparation is most likely due to the sustained release of the drug.  
Conclusion: The results indicate that the approach used could lead to a successful development of a controlled release formulation of the drug. In vivo 
studies revealed that the optimized formulation HF16 was shown significant plasma concentration with the controlled release and maintained for 24 h 
with patient compliance by reducing the dosage frequency when compared with Marketed product in the efficient management of Parkinson’s disease. 
Keywords: Tolcapone, Eudragit L100-55, Geomatrix, Tri-layer matrix tablet, In vivo bioavailability studies 
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INTRODUCTION 
Oral ingestion has long been the most convenient and commonly 
employed route of drug delivery due to its ease of administration 
and flexibility in the design of the dosage form. There are many ways 
to design modified release dosage forms for oral administration, and 
one of them is multi-layered matrix tablet. One to three layer matrix 
tablets is a drug delivery device, which comprises a matrix core 
containing the active solute and one or more barriers incorporated 
during tableting process [1]. The barrier layers delay the interaction 
of an active solute with dissolution medium, by limiting the surface 
available for the solute release and at the same time controlling 
solvent penetration rate [2, 3]. 
Hydrophilic polymers have been given considerable attention in the 
formulation of controlled release drug delivery systems for various 
drugs. HPC, HPMC and Sodium CMC & Carbopol are a few 
representative examples of the hydrophilic polymers that have been 
extensively used in the formulation of controlled release systems [4]. 
Guar gum is soluble in water; it swells in gastric fluid to produce a 
highly viscous layer around the tablet through which the drug can 
slowly diffuse [5], and is used for the fabrication of matrices with 
uniform drug release characteristics [6, 7].  
There have been different approaches to achieve zero-order drug 
release from dosage forms for sustained plasma concentration. Among 
different approaches to achieve zero-order release from hydrophilic 
matrix technologies, multilayer matrices have been widely evaluated 
and developed for commercial products under the trade name of 
Geomatrix. The technology makes use of bilayer or trilayer tablets to 
modulate the release and to achieve constant release [8].  
Tolcapone is a selective, reversible inhibitor of peripheral and 
central catechol-O-methyl transferase (COMT). Tolcapone is used to 
treat patients with Parkinson’s disease. Parkinson’s disease is a 
progressive brain disorder that causes shaking, slow movement and 
muscle stiffness [9]. 
Tolcapone is eliminated fairly quickly, with an elimination half-life of 
1.6 to 3.4 h [10]. The short half-life of tolcapone necessitated for 
fabricating extended release matrix tablets to provide a therapeutic 
amount of drug and maintain the desired drug concentration. 
Sustained release tablets are intended to take once or twice daily 
when compared with conventional dosage forms that may have to 
take three or four times daily to achieve the same therapeutic effect. 
The objective of the present study was to develop a tri-layered 
controlled release matrix tablet of tolcapone with different 
hydrophobic and hydrophilic polymers to achieve zero-order drug 
release for sustained plasma concentration. The results indicate that 
the optimized tri-layer tolcapone tablet can be successfully used for 
the treatment of Parkinson’s disease. 
MATERIALS AND METHODS 
Materials 
Tolcapone (200 mg) film coated tablets were purchased from Roche 
Inc, Mumbai. Tolcapone pure drug was a generous gift from Optimus 
Generics Ltd., Hyderabad, India. Sodium carboxyl methyl cellulose, 
Ethyl cellulose, HPMC K 4 M, HPMC K 15 M & HPMC K 100 M was 
obtained from Rubicon labs, Mumbai. Eudragit L100–55 was 
obtained from Aurobindo Pharma Ltd., Hyderabad, and Guar gum 
was gifted from MSN Labs Ltd. Hyderabad. All other chemicals used 
were of analytical grade. 
Methods 
Micromeritic studies of tolcapone  
Angle of repose 
The angle of repose is the maximum angle that can be obtained 
between the free standing surfaces of the powder heap and the 
horizontal plane. It is a characteristic related to the inter-particulate 
friction or resistance to movement between particles. The method 
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used to find the angle of repose is to pour the powder in the form of 
a conical heap on a flat surface and measure the inclined angled with 
the horizontal pile [11].  
Tan θ = h/r θ = tan-1(h/r) 
Where h = height of the heap r = radius of the heap  
Bulk density 
Bulk density is given by the mass “m” of the powder occupying a 
known volume “v” according to the relationship  
Pb = (m/v) g/cc 
It depends on particle size, shape, tendency of the particle to adhere.  
Tapped density 
Weighed powder sample was transferred to a graduated cylinder and 
was placed on tapped density apparatus, was operated for a fixed 




Based on the apparent bulk density and the tapped density, the 
percentage compressibility of the bulk drug was determined by 
using the following formula [12]. 
 
Formulation of controlled release tolcapone tri-layer matrix 
tablets 
The trilayered matrix tablets of tolcapone were prepared by direct 
compression method [13]. The first step in the formulation was to 
develop the active middle layer so as to give at least 90%drug 
release during 12 h. The release profile of this layer might not be 
of constant rate type but would be preferably of constantly falling 
rate type. This layer would then be sandwiched between barrier 
layers (Upper & Lower layers) so as to continue the drug release 
for 24 h.  
Preparation of active middle layer  
Sixteen formulations (F1-F16) for active layer were prepared by 
direct compression method using polymers like different HPMC 
grades, Sodium CMC and Ethyl Cellulose. All the formulations were 
varied in concentration of polymers, talc (1.5 mg) & magnesium 
stearate (1.5 mg) constituted in all the formulations.  
These materials were screened through ≠60 and mixed together in 
motor by using a pestle. Final mixtures were compressed by using 
12 mm diameter flat punches on a sixteen station rotary tablet press. 
Formulation of active layer was depicted in table 1. The prepared 
tablets were subjected to dissolution studies. 
Preparation of barrier layers 
The barrier layers (Upper & Lower layers) were formulated 
employing hydrophobic polymers Eudragit L100-55 and guar gum, 
which include water-soluble DCP & EC. The composition of barrier 
layers was depicted in table 1 and 2. 
 
Table 1: Formulation trails for active layer (F1-F8) 
Ingredients (mg) F1 F2 F3 F4 F5 F6 F7 F8 
Tolcapone 200 200 200 200 200 200 200 200 
HPMC K 4M 60 65 70 --- --- ---- 50 55 
HPMC K 15M --- ---- ---- 60 70 75 55 50 
HPMC K 100M --- --- --- ---- --- ---- ---- ---- 
Ethyl cellulose 35 35 30 42 40 40 20 22 
Sodium carboxy methyl cellulose 37 32.5 27 18 17 15 15 15 
Dibasic calcium phosphate 15 15 20 27 20 17 17 15 
 
Table 2: Formulation trails for active layer (F9-F16) 
Ingredients (mg) F9 F10 F11 F12 F13 F14 F15 F16 
Tolcapone 200 200 200 200 200 200 200 200 
HPMC K 4M ---- ---- ---- ---- ---- ---- ---- ---- 
HPMC K 15M ---- ---- ---- ---- ---- ---- ---- ---- 
HPMC K 100M 45 50 55 57.5 60 62.5 65 70 
Ethyl cellulose 40 35 32 30 32 30 27 30 
Sodium carboxy methyl cellulose 37 34 30 30 30 30 25 22 
Dibasic calcium phosphate 25 30 30 29.5 25 22.5 30 25 
Total wt of the tablet = 350 mg 
  
Table 3: Formulation trials of tolcapone tri layer matrix tablets 
Ingredients (mg) AF16 BF6 CF16 DF16 EF16 FF16 GF16 HF16 
Middle layer (F16) 
Tolcapone 200 200 200 200 200 200 200 200 
HPMC K 100M 70 70 70 70 70 70 70 70 
Ethyl cellulose 30 30 30 30 30 30 30 30 
Sodium carboxy methyl cellulose 22 22 22 22 22 22 22 22 
Dibasic calcium phosphate 25 25 25 25 25 25 25 25 
Barrier layer 
Eudragit L100-55 20 25 30 35 40 42.5 45 50 
Guar gum 45 40 35 30 35 35 32.5 35 
Ethyl cellulose 15 12 15 20 15 12.5 12.5 15 
Dibasic calcium phosphate 42 45 42 37 32 32 32 22 
Magnesium stearate 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 
Talc 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 
Weight of each middle layer is 350 mg & Barrier layer is 125 mg. 
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Formulations of tolcapone try layer tablets 
The powder mixtures required for active and barrier layers were 
weighed accurately and thoroughly mixed using mortar and pestle 
for about 20 min. Initially, the volume of die cavity (12 mm, round) 
was adjusted equivalence to the weight of trilayered matrix tablets 
(600 mg). Then the pre-weighed amount of powder equivalent to 
the bottom layer (125 mg) was taken and placed in the die cavity 
and slightly compressed for uniform spreading. The upper punch 
was lifted up and 350 mg of the drug containing middle active 
layer optimized formulation (F16) was placed over the bottom 
layer in the die cavity and again slightly compressed. The 
remaining volume of the die cavity was filled with a pre-weighed 
(125 mg) amount of powder equivalent to the top layer and 
compressed with the full force of compression on rotary tablets 
press to obtain tri-layered tablets. Tri-layered matrix tablets of 
each composition were compressed and tested for their friability, 
hardness, drug content and drug release characteristics with a 
suitable number of tablets for each test. 
Evaluation of tri-layer matrix tablets of tolcapone [14] 
Hardness 
The hardness often randomly picked tablets was determined using 
Monsanto hardness tester. 
Thickness 
The thickness of the tablets was measured using vernier calipers. 
Friability 
A sample of twenty randomly selected tablets were accurately 
weighed and placed in a Roche friabilator. The friabilator was 
operated for 4 min at a speed of 25 rpm. The tablets were removed 
from the friabilator, de-dusted and reweighed. The percent loss in 
weight due to abrasion and impact was calculated as, 
%Friability= (Loss in weight/Initial weight) X 100. 
Weight variation 
The weight variation test was performed as per the I. P. guidelines. 
Twenty randomly taken tablets were weighed together, and the 
average weight was determined. Each tablet was then weighed 
individually, and deviation from average weight was calculated.  
Drug content/Assay 
Five tablets were weighed individually and powdered. Then the 
powder of tablet equivalent to 200 mg was weighed and dissolved in 
phosphate buffer 7.4 pH, the solution was filtered and diluted using 
phosphate buffer pH7.4 and then the drug content was analyzed 
using UV spectrophotometer at 257 nm.  
Swelling and erosion studies 
The swelling experiment was conducted on the prepared tablets 
using USP dissolution apparatus II at a rotational speed of 50 rpm. 
The medium used was 900 ml phosphate buffer pH 7.4 at 37 °C. The 
swelling study was done up to 10h. The tablets were removed using 
a small basket, and swollen weight of each tablet was determined. 
The % of swelling was calculated according to the formula:  
 
In-vitro drug releases profile 
In vitro drug release studies for developed trilayer matrix tablets 
were carried out by using dissolution apparatus II paddle type 
(Electrolab TDL-08L). The drug release profile was studied in 900 ml 
Phosphate buffer pH 7.4 at 37±0.5 °C temperature. The amount of 
drug release was determined by UV-visible spectrophotometer 
(Shimadzu UV 1800) at 257 nm. 
Drug release kinetics  
To describe the kinetics of the drug release from matrix tablet, 
mathematical models such as Zero order. First order, and Higuchi, 
models were used. The criterion for selecting the most appropriate 
model was chosen on the basis of the goodness or fit test. 
Drug-excipient compatibility studies 
Fourier transforms infrared spectroscopy (FTIR) 
FTIR spectra for the pure drug, physical mixture and optimized 
formulations were recorded using a Fourier transform Infrared 
spectrophotometer. The analysis was carried out in Shimadzu-IR 
Affinity 1 Spectrophotometer. The samples were dispersed in KBr 
and compressed into disc/pellet by application of pressure. The 
pellets were placed in the light path for recording the IR spectra. The 
scanning range was 400-4000 cm-1 and the resolution was 1 cm-1. 
Differential scanning calorimetry (DSC) 
Differential scanning calorimetry (DSC) studies were carried out 
using DSC 60, having TA60 software, Shimadzu, Japan. Samples were 
accurately weighed and heated in sealed aluminum pans at a rate of 
10 °C/min between 25 and 350 °C temperature range under a 
nitrogen atmosphere. Empty aluminum pan was used as a reference. 
Stability studies  
The stability study of the formulated tolcapone trilayer tablets was 
carried out under different conditions according to ICH guidelines using 
stability chamber (REMI make). Accelerated Stability studies were 
carried out at 40 °C/75 % RH for the best formulations for 6 mo. The 
tablets were characterized by the hardness, friability, drug content and 
cumulative % drug released during the study stability period.  
Pharmacokinetic studies 
Animal preparation  
Male rabbits were (weighing 2-3 kg) selected for this study, all the 
animals were healthy during the period of the experiment. Animals 
were maintained at room temperature 25 °C, Relative Humidity 45% 
and 12 h alternate light and dark cycle with 100 % fresh air 
exchange in animal rooms, uninterrupted power and water supply 
and rabbits were fed with standard diet and water ad libitum. The 
protocol of animal study was approved by the institutional animal 
ethics committee (IAEC NO: P34/VCP/IAEC/2015/2/DBP/AE12). 
In vivo study design 
The Rabbits were randomly divided into two groups each group 
contains six animals. The group A was received prepared tolcapone 
matrix tablets (200 mg); marketed product was administered group 
B with an equivalent dose of animal body weight. Blood samples 
(approximately 0.5 ml) were obtained with syringes by marginal ear 
vein at 0, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 20 and 24h post-dose. During 
collection, blood sample has been mixed thoroughly with heparin in 
order to prevent blood clotting. Plasma was separated by 
centrifugation of the blood at 5000 rpm in cooling centrifuge for 5 
min to 10 min and stored frozen at −20 °C until analysis.  
Preparation of plasma samples for HPLC analysis  
Rabbit plasma (0.5 ml) samples were prepared for chromatography 
by precipitating proteins with 2.5 ml of ice-cold absolute ethanol for 
each 0.5 ml of plasma. After centrifugation, the ethanol was 
transferred into a clean tube. The precipitate was resuspended with 
1 ml of acetonitrile by vortexing for 1 min. After centrifugation 
(5000–6000 rpm for 10 min), the acetonitrile was added to the 
ethanol and the organic mixture was taken to near dryness by a 
steam of nitrogen at room temperature.  
For HPLC C8 column with 5μm particle size and the mobile phase 
consisting of Acetonitrile: Methanol (90:10). The flow rate was 1.0 
ml/min, and the effluents were monitored at 270 nm. Internal 
standard carbidopa was used. The retention time of tolcapone and 
carbidopa was 2.3 min and 4.2 respectively [15]. 
Pharmacokinetic analysis  
The pharmacokinetic parameters, peak plasma concentrations (Cmax) 
and time to reach peak concentration (tmax) were directly obtained 
from concentration-time data. In the present study, AUC0-t refers to 
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the AUC from 0 to 24 h, which was determined by linear trapezoidal 
rule and AUC0-α refers to the AUC from time at zero hours to infinity.  
The AUC0-α was calculated using the formula AUC0-t+[Clast/K] where C 
last is the concentration in µg/ml at the last time point and K is the 
elimination rate constant. 
Various pharmacokinetic parameters like the area under the curve 
[AUC], elimination half-life (t½). The volume of distribution (Vd), 
total clearance (ClT) and mean residence time for each subject using 
a non-compartmental pharmacokinetic programme. The 
pharmacokinetic parameters were performed by non-
compartmental analysis using Win Nonlin 3.3® pharmacokinetic 
software (Pharsight Mountain View, CA USA). All values are 
expressed as the mean±SD. Statistical analysis was performed with 
Graph Pad Instate software (version 3.00, Graph Pad Software, San 
Diego, CA, USA) using one-way analysis of variance (ANOVA) 
followed by Tukey–Kramer multiple comparison test. The difference 
with p<0.05 was considered statistically significant. 
RESULTS AND DISCUSSION 
Micromeritic studies of tolcapone  
All the powder mixture belonging to different formulations of tolcapone 
trilayer tablets was tested for micrometric studies like bulk density, 
tapped density, the angle of repose and Carr’s index in order to 
determine the flow properties. All the formulations AF16 to HF16 
showed good flow properties and the results are summarized in table 4. 
 
Table 4: Powder flow properties of tri layer tablets 
Powder properties AF16 BF16 CF16 DF16 EF16 FF16 GF16 HF16 
Bulk density (g/cc) 0.7251±0.07 0.7125±0.41 0.612±0.21 0.7050±0.54 0.719±0.23 0.682±0.68 0.645±0.67 0.722±0.46 
Tapped density (g/cc) 0.774±0.18 0.760±0.94 0.679±0.18 0.768±0.22 0.785±0.83 0.756±0.83 0.791±0.044 0.795±0.83 
Angle of repose(o) 32.69±0.64 33.93±0.67 32.12±0.32 32.09±0.41 27.76±0.65 32.09±0.27 27.15±0.02 25.39±0.66 
Carr’s index 12.02±0.95 12.22±0.13 11.29±0.61 10.81±0.51 9.23±0.44 11.72±0.55 9.38±0.55 8.25±0.94 
n=3±SD 
 
Table 5: Cumulative % drug release of different formulations of tolcapone active layer (F1-F8) 
Time (h) F1 F2 F3 F4 F5 F6 F7 F8 
1 23.1±0.05 18.6±0.02 19.55± 19.5± 34.2±0.06 18.4±0.08 35.7±0.01 30.7±0.05 
2 32.1±0.01 27.2±0.05 45.89±0.04 46.7±0.05 49.5±0.02 58.4±0.06 63.9±0.08 45.9±0.08 
4 32.1±0.02 58.2±0.05 65.48±0.05 49.4±0.06 50.7±0.05 58.8±0.04 67.5±0.07 59.4±0.08 
6 49.2±0.04 90.1±0.02 76.78±0.06 80.7±0.08 51.5±0.03 63.7±0.02 77.7±0.08 90.7±0.02 
8 54.4±0.02 91.2±0.03 94.15±0.02 83.7±0.05 54.7±0.04 76.4±0.01 81.7±0.06 91.8±0.09 
10 57.3±0.04 95.1±0.06 95.28±0.03 85.7±0.04 63.7±0.07 80.7±0.03 90.4±0.08 95.7±0.05 
12 67.2±0.05 94.4±0.05 96.47±0.05 89.1±0.06 65.7±1.06 86.4±0.03 95.5±0.07 93.4±0.06 
n=3±SD 
 
Table 5: Cumulative % drug release of formulations F9-F16 
Time(h) F9 F10 F11 F12 F13 F14 F15 F16 
1 11.4±0.01 15.1±0.07 20.4±0.04 17.5±0.07 19.7±0.05 23.5±0.08 20.7±0.05 22.5±0.04 
2 23.5±0.05 27.7±0.08 36.5±0.05 26.6±0.08 34.5±0.06 45.7±0.05 34.5±0.04 35.5±0.07 
4 32.6±0.04 58.8±0.06 49.8±0.09 40.5±0.06 40.6±0.06 63.8±0.06 46.8±0.05 50.6±0.03 
6 33.2±0.07 67.5±0.06 67.8±0.07 49.5±0.06 45.8±0.05 72.8±0.09 78.5±0.04 70.6±0.05 
8 49.5±0.05 90.5±0.02 76.9±0.05 72.8±0.06 54.5±0.05 79.2±0.04 80.2±0.05 81.8±0.05 
10 54.9±0.05 91.3±0.03 81.8±0.06 80.5±0.04 63.2±0.06 90.8±0.05 90.6±0.07 90.8±0.06 
12 77.5±0.05 94.2±0.04 95.4±0.09 83.7±0.05 68.9±0.07 92.5±0.04 94.6±0.05 98.5±005 
n=3±SD 
 
Preparation of active middle layer  
The matrix tablets of tolcapone were prepared without the barrier 
layers. All the formulation trails were subjected to in vitro 
dissolution to determine the release profiles. 
 
 
Fig. 1: Cumulative % drug release of formulations F1-F8 
 
Fig. 2: Cumulative % drug release of formulations F8-F16 
 
From the above results, the formulation F16 was decided as 
optimized formulation based on the highest drug release i.e. 
98.5±005% within 12h when to compare with other formulations 
Potturi et al. 
Int J Pharm Pharm Sci, Vol 8, Issue 3, 318-324 
322 
(table 5 and 6; fig. 1 and 2). Formulation F16 was choosen as an 
active layer for further studies. 
 
 
Fig. 3: Tolcapone trilayer matrix tablets 
Evaluation of trilayer matrix tablets of tolcapone 
The tolcapone, trilayer matrix tablets, are shown in fig. 3. 
Sustained/Controlled release tablets generally have hardness in 
the range of 7-10 kg/cm2. In the case of trilayer tablets the 
hardness of the tablets was found to be 7.1 to 8.6 kg/cm2. The 
friability of the formulations was found to be less than 1% and 
hence the tablets with lower friability may not break during 
handling on machines and or shipping. All the batches of the 
tablets complied with the variation weight limits as per the IP. 
The drug content in the different formulation was highly 
uniform, and the results are depicted in table 6. 
 
Table 6: Evaluation parameters tolcapone trilayer matrix tablets 




Weight variation** (mg) %Drug content*** 
AF16 5.60 7.1±0.23 0.34 473±10 97.1 
BF16 5.72 7.6±0.42 0.23 473±14 96.4 
CF16 5.54 7.4±0.41 0.35 476±16 98.8 
DF16 5.73 7.1±0.32 0.26 473±14 97.6 
EF16 5.71 8.2±0.59 0.33 473±13 97.4 
FF16 5.62 7.8±0.22 0.26 472±17 97.5 
GF16 5.54 8.6±0.55 0.27 472±15 98.1 
HF16 5.70 8.3±0.15 0.21 474±18 99.0 
*n=3; **n=20±SD; n=5±SD*** 
 
Table 7: In-vitro dissolution profile of tolcapone trilayered tablets 
Time (h) AF16 BF16 CF16 DF16 EF16 FF16 GF16 HF16 
1 6.12±0.01 5.65±0.07 5.34±0.04 6.12±0.05 7.23±0.05 6.23±0.06 5.24±0.06 6.2.23±0.09 
2 10.34±0.02 8.67±0.05 8.23±0.04 11.11±0.04 10.43±0.04 10.12±0.06 11.45±0.05 10.11±0.08 
4 12.45±0.04 9.89±0.04 16.14±0.07 22.12±0.05 10.45±0.05 12.44±0.05 13.56±0.05 19.21±0.07 
6 21.65±0.04 20.56±0.05 24.12±0.05 25.13±0.06 13.76±0.07 16.88±0.05 18.45±0.08 25.45±0.06 
8 32.76±0.5 31.76±0.04 36.67±0.05 36.14±0.05 22.76±0.05 20.43±0.09 30.87±0.06 39.76±0.07 
10 49.89±0.02 49.56±0.08 44.87±0.06 49.12±0.04 44.78±0.04 47.23±0.05 42.34±0.07 46.88±0.04 
12 54.76±0.04 54.34±0.04 54.34±0.07 56.34±0.05 51.98±0.06 49.23±0.06 50.56±0.08 50.45±0.08 
16 60.34±0.06 60.45±0.04 58.78±0.05 64.11±0.04 62.56±0.03 60.23±0.06 64.57±0.09 65.34±0.05 
18 69.45±0.07 65.56±0.05 6013±0.05 66.45±0.05 67.43±0.04 61.54±0.05 70.87±0.07 69.23±0.05 
20 72.13±0.05 72.12±0.07 70.51±0.07 73.12±0.04 69.65±0.05 74.13±0.04 78.66±0.05 75.23±0.08 
24 90.11±0.04 93.77±0.5 95.23±0.05 94.56±0.04 92.34±0.04 93.24±0.04 90.43±0.07 99.43±0.05 
n=3±SD 
 
The physical properties of all the tablets are within the limits and the 
hardness ranges in between 5-7 kg/cm2. The assay results showed the 
percentage of the drug from 95-99. The tablets did not develop any 
cracks during manufacturing, and there occurred no layer separation 
during the process of dissolution. Hence, all the tablets were subjected 
to in vitro dissolution test to determine the release profiles. 
Swelling studies 
In phosphate buffer pH 7.4, HPMC K 100M showed the good swelling 
property. In trilayer tablets of tolcapone, HF16 showed the highest 
degree of swelling index 212.24%, whereas in AH16 showed least 
swelling with a swelling index of 124.35%.  
In vitro dissolution studies of tolcapone trilayer tablets  
The In vitro drug profile of tolcapone from different formulations 
was carried out in phosphate buffer pH 7.4, and the results are 
depicted in table 7 & fig. 4.  
The trilayer tablets extended the drug release up to 24 h. The 
highest drug release was found in the formulation HF16 i. e 
99.43±0.05% within 24 h. HF16 was found to be optimized 
formulation based on the dissolution and other evaluation 
parameters. The in vitro drug release profile from tolcapone 
marketed product was shown in table 8 and fig. 5 and found to 
be 95.25% within 60 min. 
In-vitro dissolution studies of tolcapone trilayered tablets 
formulated in different trials 
 
Fig. 4: Cumulative percentage drug release from formulation 
HF16 and marketed product 
 
 
Fig. 5: Comparison of cumulative percentage drug release of 
tolcapone from marketed product and optimized formulation 
HF16 
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Table 8: Cumulative% drug release marketed product 








Table 9: Drug release kinetics of tolcapone optimized 
formulation (HF16) and marketed product 
Formulation code Zero order First order Higuchi model 
HF16 0.992 0.836 0.974 
Marketed product 0.703 0.952 ---- 
 
In the present study drug release mechanism is best fitting to zero 
order and Higuchi model because regression coefficient was seen 
closest to 1 in these models which conforms diffusion assisted 
mechanism of release. The marketed product was explained by first 
order kinetics as the plot showed the highest linearity (r²=0.952) as 




Fig. 6: FT-IR spectrum of pure drug tolcapone 
 
 




Fig. 8: FT-IR spectrum of tolcapone optimized formulation HF16 
 
There was no alteration in peaks of tolcapone pure drug (fig. 6) and 
optimized formulation (fig. 8), suggesting that there was no 
interaction between drug & excipients. FT-IR spectrum of pure drug 
and other polymers are shown in (fig. 7). There is additional peaks 
appeared or disappeared hence no significant changes in peaks of 
optimized formulation was observed when compared to the pure 
drug, indicating the absence of any interaction.  
DSC studies  
 
Fig. 9: DSC thermogram of tolcapone pure drug (A) and 
optimized formulation HF16 (B) 
 
DSC was used to detect an interaction between tolcapone and 
excipients. The thermogram of tolcapone exhibited a sharp 
endotherm melting point at 140 °C. The thermogram of the 
optimized formulation of tolcapone exhibited a sharp endotherm 
melting point at 143 °C. The DSC thermogram retained properties of 
tolcapone, as well as polymer properties. There is no considerable 
change observed in melting endotherm of the drug in the optimized 
formulation (fig. 9). It indicates that there is no interaction between 
drug & excipients used in the formulation. 
Stability studies 
The optimized trilayer matrix tablets (HF16) formulation was 
subjected to stability studies for 6 mo to evaluate its stability and the 
integrity of the dosage form. There was no significant change 
observed in the friability, hardness, cumulative % drug content and 
in vitro drug release of HF16 at 40 °C/75 % RH for 6 mo. The tablets 
were characterized for the hardness, friability, drug content and 
cumulative % drug released during the study stability period. From 
these results, it was concluded that optimized formulation was 
stable and retained their original properties with minor differences. 
Pharmacokinetic studies 
 
Fig. 10: Plasma Concentrations of tolcapone optimized 




Mean plasma concentration profiles of prepared tolcapone optimized 
formulation and marketed product are presented in fig. 10. Tolcapone 
optimized formulation exhibited as sustained release in vivo when 
compared with marketed product. All the pharmacokinetics 
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parameters displayed in table 10. Tolcapone reference drug was 
available in plasma within two hours after its oral 
administration. The Tmax of the test tolcapone was significantly 
different (p<0.05) from that of the standard. Low Tmax value for 
the reference drug (2.02±0.02h) indicates rapid absorption while 
the higher Tmax of the test drug (6.00±0.04h) suggests slower 
absorption. This delayed absorption of test preparation is most 
likely due to the sustained release of the drug. On the other hand, 
the Cmax of the marketed product was significantly different from 
the test preparation. The half-life of the reference preparation was 
low which indicates rapid removal of the drug from plasma. This 
was also supported by the high elimination rate constant value. On 
the other hand, the test formulation exhibited higher half-life and 
low elimination rate constant values indicating slower drug 
disposition and prolonged effect. However, the AUC0-∞ values for 
the two formulations were significantly different. This suggests 
that the tolcapone contained in the test product was completely 
absorbed. 
 
Table 10: Comparison of pharmacokinetic parameters of tolcapone optimized formulation (HF16) and marketed product 
Parameters Tolcapone optimized formulation (HF16) Marketed product 
Cmax (µg/ml) 8960.21±0.05 9575.15±0.08 
AUC 0-t (µg h/ml) 39430.65±0.12 32452.25±0.02 
AUC0-∞ (µg h/ml) 44197.75±0.14 38478.14±0.02 
Tmax (h) 6.00±0.04 2.02±0.02 
t 1/2 (h) 7.5±0.014 4.15±0.05 
 
DISCUSSION 
These results revealed that the continuous and steady state release 
of tolcapone from the trilayered matrix optimized tablet was 
obtained when compared with a marketed conventional tablet, 
where dosage frequency can be reduced from 3-4 times to one time. 
At present tolcapone extended-release tablets are not available in 
the market. The optimized formulation of tolcapone HF16 has 
shown the drug release for the period of 24 h. The maintenance of 
continuous and steady plasma concentration of the drug is essential 
for the management of Parkinson’s disease. 
CONCLUSION 
Our studies highlighted the potential use of controlled release 
trilayer matrix tablets as an efficient strategy for the oral delivery of 
tolcapone. From this study, it was concluded that trilayer matrix 
tablets of tolcapone can be successfully prepared by direct 
compression technique using different polymers combination. Based 
on the evaluation parameters, drug dissolution profile and release 
drug kinetics HF16 was found to be optimized formulation. The drug 
release from HF16 was found to fit zero order and best fitted to 
Higuchi’s model confirming to be the diffusion assisted mechanism. 
FT-IR & DSC studies revealed that there was no interaction between 
the drug and polymers used in the formulations. In vivo 
bioavailability studies were conducted for optimized tolcapone 
trilayer tablets and marketed product, In vivo studies indicating that 
the optimized tolcapone formulation was shown sustained release 
patterns where marketed product was shown immediate release. So 
the optimized formulation was shown significant plasma 
concentrations with sustained release and maintained for 24 h. The 
optimized formulation of tolcapone trilayer matrix tablet was shown 
significant plasma concentration with the controlled release and 
maintained for 24 h with patient compliance by reducing the dosage 
frequency when compared with marketed product in the efficient 
management of Parkinson’s disease. 
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